These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37387459)

  • 1. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers.
    Gibson LL; Abdelnour C; Chong J; Ballard C; Aarsland D
    Curr Opin Neurol; 2023 Aug; 36(4):264-275. PubMed ID: 37387459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia.
    Thomas AJ; Mahin-Babaei F; Saidi M; Lett D; Taylor JP; Walker L; Attems J
    Alzheimers Res Ther; 2018 Mar; 10(1):27. PubMed ID: 29490691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies.
    Abdelnour C; Ferreira D; Oppedal K; Cavallin L; Bousiges O; Wahlund LO; Hort J; Nedelska Z; Padovani A; Pilotto A; Bonanni L; Kramberger MG; Boada M; Westman E; Pagonabarraga J; Kulisevsky J; Blanc F; Aarsland D
    Neuroimage Clin; 2020; 27():102333. PubMed ID: 32674011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies.
    Fixemer S; Ameli C; Hammer G; Salamanca L; Uriarte Huarte O; Schwartz C; Gérardy JJ; Mechawar N; Skupin A; Mittelbronn M; Bouvier DS
    Acta Neuropathol Commun; 2022 Mar; 10(1):36. PubMed ID: 35296366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies: A Systematic Review and Meta-analysis.
    Zhang Q; Li J; Quan W; Liu L; Qin Y; Pei X; Su H; Xu J; Chen J
    Alzheimer Dis Assoc Disord; 2022 Oct-Dec 01; 36(4):368-373. PubMed ID: 36183420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.
    Colom-Cadena M; Gelpi E; Charif S; Belbin O; Blesa R; Martí MJ; Clarimón J; Lleó A
    J Neuropathol Exp Neurol; 2013 Dec; 72(12):1203-12. PubMed ID: 24226269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
    Chaudhry A; Houlden H; Rizig M
    J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics.
    Noguchi-Shinohara M; Ono K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
    Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
    Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.